甲氨蝶呤与艾拉莫德治疗难治性类风湿关节炎的临床疗效评价(1)
[摘要] 目的 評价甲氨蝶呤与艾拉莫德治疗难治性类风湿关节炎的临床疗效。 方法 选择我院2017年6月～2019年1月收治的116例难治性类风湿关节炎患者按照随机数字表法均分两组，对照组58例患者口服甲氨喋呤片治疗，试验组58例患者在对照组基础上辅以艾拉莫德联合治疗，对其临床疗效进行评价。 结果 经治疗后，试验组患者的疾病活动性评分、血清中TNF-α、VEGF含量及RF、ESR及CRP等指标分别为(3.15±1.21)分、(226.13±6.31)pg/mL、(814.04±14.43)pg/mL、(13.12±3.22)U/mL、(11.44±2.14)mm/h、(9.13±1.82)U/mL;对照组患者的疾病活动性评分、血清中TNF-α、VEGF含量及RF、ESR及CRP等指标分别为(5.87±1.73)分、(310.82±9.59)pg/mL、(1006.68±11.14)pg/mL、(46.80±5.33)U/mL、(32.84±6.15)mm/h、(27.47±7.24)U/mL。试验组有较大程度的改善，组间数据差异有统计学意义(P<0.05)。试验组治疗总有效率高于对照组，差异有统计学意义(P<0.05)。 结论 甲氨蝶呤与艾拉莫德治疗难治性类风湿关节炎的临床疗效显著，能够有效改善患者临床症状，安全性高，可长时间服用。
[关键词] 甲氨蝶呤;艾拉莫德;难治性类风湿关节炎;临床疗效;评价
[中图分类号] R593.22 [文献标识码] B [文章编号] 1673-9701(2020)08-0106-04
Clinical efficacy evaluation of methotrexate and iguratimod in treatment of refractory rheumatoid arthritis
JU Yanjuan GUO Dibin CHEN Hu LI Wenqi
Department of Rheumatism and Immunology， First Affiliated Hospital of Gannan Medical University， Ganzhou 341000， China
[Abstract] Objective To evaluate the clinical efficacy of methotrexate and iguratimod in the treatment of refractory rheumatoid arthritis. Methods One hundred and sixteen patients with refractory rheumatoid arthritis admitted to our hospital from June 2017 to January 2019 were selected and divided into two groups according to the random number table method. In the control group， 58 patients were treated with methotrexate orally. In the experimental group， 58 patients were treated with iguratimod combined with methotrexate. The clinical efficacy of the two groups was evaluated. Results After treatment， the disease activity score， serum TNF-α， VEGF content， RF， ESR and CRP of the experimental group were(3.15±1.21) points， (226.13±6.31)pg/mL， (814.04±14.43) pg/mL， (13.12±3.22)U/mL， (11.44±2.14)mm/h， and (9.13±1.82)U/mL， respectively. The disease activity score， serum TNF-α， VEGF content， RF， ESR and CRP of the control group were (5.87±1.73) points， (310.82±9.59)pg/mL， (1006.68±11.14)pg/mL， (46.80±5.33)U/mL， (32.84±6.15)mm/h， and (27.47±7.24)U/mL， respectively. The data in the experimental group were greatly improved， and the differences of the data between the groups were statistically significant(P<0.05). The total effective rate of the experimental group was higher that of the control group， the difference was statistically significant(P<0.05). Conclusion Methotrexate combined with iguratimod has significant clinical efficacy in the treatment of refractory rheumatoid arthritis， which can effectively improve the clinical symptoms of patients. It is safe and can be taken for a long time., 百拇医药(居艳娟 郭迪斌 陈琥 李文琦)
[关键词] 甲氨蝶呤;艾拉莫德;难治性类风湿关节炎;临床疗效;评价
[中图分类号] R593.22 [文献标识码] B [文章编号] 1673-9701(2020)08-0106-04
Clinical efficacy evaluation of methotrexate and iguratimod in treatment of refractory rheumatoid arthritis
JU Yanjuan GUO Dibin CHEN Hu LI Wenqi
Department of Rheumatism and Immunology， First Affiliated Hospital of Gannan Medical University， Ganzhou 341000， China
[Abstract] Objective To evaluate the clinical efficacy of methotrexate and iguratimod in the treatment of refractory rheumatoid arthritis. Methods One hundred and sixteen patients with refractory rheumatoid arthritis admitted to our hospital from June 2017 to January 2019 were selected and divided into two groups according to the random number table method. In the control group， 58 patients were treated with methotrexate orally. In the experimental group， 58 patients were treated with iguratimod combined with methotrexate. The clinical efficacy of the two groups was evaluated. Results After treatment， the disease activity score， serum TNF-α， VEGF content， RF， ESR and CRP of the experimental group were(3.15±1.21) points， (226.13±6.31)pg/mL， (814.04±14.43) pg/mL， (13.12±3.22)U/mL， (11.44±2.14)mm/h， and (9.13±1.82)U/mL， respectively. The disease activity score， serum TNF-α， VEGF content， RF， ESR and CRP of the control group were (5.87±1.73) points， (310.82±9.59)pg/mL， (1006.68±11.14)pg/mL， (46.80±5.33)U/mL， (32.84±6.15)mm/h， and (27.47±7.24)U/mL， respectively. The data in the experimental group were greatly improved， and the differences of the data between the groups were statistically significant(P<0.05). The total effective rate of the experimental group was higher that of the control group， the difference was statistically significant(P<0.05). Conclusion Methotrexate combined with iguratimod has significant clinical efficacy in the treatment of refractory rheumatoid arthritis， which can effectively improve the clinical symptoms of patients. It is safe and can be taken for a long time., 百拇医药(居艳娟 郭迪斌 陈琥 李文琦)
参见：首页 > 医疗版 > 疾病专题 > 骨科 > 慢性非化脓性关节炎或关节病 > 类风湿性关节病